Clinical Trial: Fish Oil for the Treatment of Depression in Patients with Multiple Sclerosis

This study is currently recruiting patients.

Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
National Institutes of Health (NIH)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)

Purpose

This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication.

Study hypothesis: Three months of fish oil supplementation will improve depression scores on the Montgomery-Asberg depression rating scale (MADRS) or Beck Depression Inventory (BDI) better than placebo.

Condition Intervention Phase
Multiple Sclerosis
Depression
 Drug: Fish oil capsules
Phase I
Phase II

MedlinePlus related topics:  Depression;   Multiple Sclerosis

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title: Fish Oil As an Adjunct Therapy for Depression in Multiple Sclerosis

Further Study Details: 
Primary Outcomes: Three month change in MADRS scores; three month change in interferon-gamma (IFN-g) levels
Secondary Outcomes: Whether the change in IFN-g level is correlated with the change in MADRS scores
Expected Total Enrollment:  60

Study start: May 2005;  Expected completion: June 2009

Depression occurs in 50% to 60% of all individuals with MS. Evidence suggests that the omega-3 fatty acids in fish oil supplements can significantly reduce depression with a low risk of side effects. Therefore, fish oil supplements may be a safe adjunctive therapy to improve the therapeutic benefits of antidepressants. This study will determine the effectiveness of fish oil supplements in reducing depression in MS patients who are taking antidepressant medication.

This study will last 3 months. Participants will be randomly assigned to receive either fish oil supplements or placebo daily for 3 months. At the end of 3 months, participants who show an improvement in their depressive symptoms will have the option to continue their treatment for an additional 3 months. Participants will do no respond to treatment will be excused from the study. All participants will remain on their antidepressants and MS medication throughout the study. Participants will have weekly study visits. At each visit, participants will be asked about their general health, and self-report scales will be used to assess depressive symptoms. Medication adherence will be monitored by pill counts and through red blood cell fatty acid analysis. Blood collection will occur at study start and at study completion.

Eligibility

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Diagnosis of relapsing-remitting MS
  • Diagnosis of depressive disorder
  • Score between 11 and 30 on the Montgomery-Asberg Depression Rating Scale (MADRS)
  • Score of 25 or greater on the Mini-Mental State Examination (MMSE)
  • Currently taking antidepressant medication for at least 3 months prior to study entry

Exclusion Criteria:

  • Currently taking fatty acid supplements
  • Consume more than 6 oz of fish per week within 1 month prior to study entry
  • Severe depression
  • Suicidal thoughts
  • Other psychological disorders
  • Currently taking more than two types of antidepressants
  • Any serious medical condition that would interfere with the study
  • Worsening of MS symptoms or corticosteroid treatment within 1 month prior to study entry
  • Current enrollment in another fish oil study
  • Pregnancy

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00122954

Rachel R. Frank, BA      503-494-7963    frankra@ohsu.edu

Oregon
      Oregon Health and Science University, Portland,  Oregon,  97239,  United States; Recruiting
Rachel R. Frank, BA  503-494-7963    frankra@ohsu.edu 
Lynne Shinto, ND  503-494-5035    shintol@ohsu.edu 
Lynne Shinto, ND,  Principal Investigator
Dennis Bourdette, MD,  Sub-Investigator

Study chairs or principal investigators

Lynne Shinto, ND,  Principal Investigator,  Oregon Health and Science University   

More Information

Click here for more information about complementary and alternative medicine-related research at Oregon Health and Science University

Click here for more information about research studies at the Multiple Sclerosis Center of Oregon

Publications

Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002 Mar;159(3):477-9.

Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003 Aug;13(4):267-71. Erratum in: Eur Neuropsychopharmacol. 2004 Mar;14(2):173.

Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002 Oct;59(10):913-9.

Study ID Numbers:  AT002155-01
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 21, 2005
ClinicalTrials.gov Identifier:  NCT00122954
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-07-26

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us